One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
about
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegalyRapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extensionClinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.Clinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomasEfficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegalyCurrent pharmacotherapy for acromegaly: a review.Treatment strategies for acromegaly.Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective.Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.Pharmacokinetic evaluation of lanreotide.Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefitsManagement options for persistent postoperative acromegaly.Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications.The place of medical treatment of acromegaly: current status and perspectives.Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.Lanreotide autogel in acromegaly - a decade on.A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry.Adverse events associated with somatostatin analogs in acromegaly.Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.Multi-modal management of acromegaly: a value perspective.Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles.Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days.Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA).Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)
P2860
Q26777682-BAD687CC-6F47-4604-BD45-1EEE934E9395Q33595081-C62CD0D8-5CE4-4DFD-A4C2-7C30A628A0A4Q33772673-2D277B3B-15E7-4030-90A9-58DC70B4117BQ34658946-7FBEF938-A44A-4562-9605-D5EBB828D986Q35104263-76A6B682-159D-46CF-B0B3-19E1CFAE758EQ36236809-50001A51-D93B-4306-832D-A40D8A3F3D98Q36301564-4B054CDB-93DF-43AE-88F5-7BD64BCA66EFQ36302865-ED4F61D2-8244-47CB-AABD-C75F47D89F4AQ36499678-CE899B04-9F09-407B-BD9C-5F3DC7837E21Q37029532-537C236C-76A0-4327-85B4-34DE37927F84Q37519612-B8EB7082-F9EC-4CBA-A197-E7D7E756C52CQ37780553-A0E76F79-8F16-44A6-94D8-9DB5932F6489Q37980741-3E2E1697-5BCF-4218-BC1B-23664AF1EE65Q38049832-9A0C053D-1CD6-41C8-A2A5-71A2F2BFE3E1Q38073189-94A2586C-3B5B-4037-8F4F-8E5F2827993CQ38100275-91012078-5ED3-4CEE-B703-85F1AA134E08Q38246440-57944372-DCFA-4658-8E1F-FCA7DF5B277DQ38259409-1E0D5ECB-6A4B-4BE0-B3AF-C6AA5C1EB10DQ38373377-E185C89C-94A5-4AE2-B542-38DD7B12961AQ38548973-F9EC06CB-405D-4D4C-AF8A-CA919E31C34EQ39372287-9A116BED-F431-4411-B4C5-6F41DAD27EC2Q41627761-178CDCFD-20D1-4AC3-85AE-16ACA51EFF99Q43078115-F2CF3FBF-ACE0-4EED-AC87-A152AA6FBC70Q46542233-BF86CC2D-94BE-40E2-9D45-72FFC8C905D3Q46789846-B2DA5DCC-6148-421F-8B38-5271F3BF25F4Q46907017-F7B2BBF9-A191-40C7-8DF7-AE055913DBBDQ47936712-AB70466A-96FB-48AB-A3A3-F77C35BA031BQ57142659-762D6315-A69C-4E23-8470-FDE94B81DE9A
P2860
One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
One-year follow-up of patients ...... d doses of lanreotide Autogel.
@en
One-year follow-up of patients ...... d doses of lanreotide Autogel.
@nl
type
label
One-year follow-up of patients ...... d doses of lanreotide Autogel.
@en
One-year follow-up of patients ...... d doses of lanreotide Autogel.
@nl
prefLabel
One-year follow-up of patients ...... d doses of lanreotide Autogel.
@en
One-year follow-up of patients ...... d doses of lanreotide Autogel.
@nl
P2093
P2860
P1476
One-year follow-up of patients ...... d doses of lanreotide Autogel.
@en
P2093
A M Pico Alfonso
D R Cullen
Group for Lanreotide Autogel Long-Term Study on Acromegaly
J Schopohl
M J Valimaki
P2860
P304
P356
10.1111/J.1365-2265.2004.02045.X
P577
2004-06-01T00:00:00Z